TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).

Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device thrombosis following LAAC. The efficacy outcome measure was device thrombosis evaluated by a transesophageal echocardiogram, and the safety outcome measure was the combined outcome of all-cause mortality, bleeding, stroke, or device thrombosis.

Findings showed no statistical significance in the primary efficacy endpoint of device related thrombosis between the two groups; however, a significant reduction in the primary safety endpoint of adverse events was seen in the short-term anticoagulation group compared to the DAPT group.

Interview Questions: 
1. What specific gaps in clinical knowledge was the ANDES trial aiming to address?
2. What was the study design and patient population?
3. What were the key findings in terms of the safety and efficacy outcome measures?
4. How should these findings impact clinical practice?
5. What further research is needed to refine post-LAAC management strategies?

For more content from TCT 2025 head to the Late-breaking Science Video Collection.

Recorded on-site at TCT Conference in San Francisco, 2025.
Editor: Yazmin Sadik.
Video Specialist: Dan Brent.

Support: This is an independent interview produced by Transcatheter Academy.